Comparative Pharmacology
Head-to-head clinical analysis: TRAVASOL 2 75 IN DEXTROSE 20 IN PLASTIC CONTAINER versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 10 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRAVASOL 2 75 IN DEXTROSE 20 IN PLASTIC CONTAINER versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 10 IN PLASTIC CONTAINER.
TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER vs TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides exogenous amino acids and dextrose to meet caloric and protein requirements in patients who cannot tolerate enteral nutrition. Amino acids are used for protein synthesis and as substrates for gluconeogenesis and other metabolic pathways.
Travasol 2.75% with electrolytes in dextrose 10% is a parenteral nutrition solution. Amino acids provide substrate for protein synthesis, dextrose supplies calories, and electrolytes maintain acid-base balance and osmotic equilibrium.
Intravenous infusion: 500 mL to 1000 mL over 24 hours, titrated to provide 2.75% amino acids and 20% dextrose as part of parenteral nutrition. Rate based on glucose tolerance and metabolic needs.
Intravenous infusion. Dosage depends on caloric and nitrogen requirements, generally 1-3 L per day in adults providing 4.25 g amino acids and 100 g dextrose per liter.
None Documented
None Documented
Amino acids: not applicable (endogenous metabolites). Dextrose: <15 minutes; clinical context: continuous infusion required to maintain glucose homeostasis.
Not applicable as a single entity; components have variable half-lives. Dextrose has elimination half-life of ~2-4 hours; amino acids have variable half-lives based on individual metabolic rates.
Amino acids and dextrose are metabolized; excess nitrogen is excreted primarily as urea in urine. Dextrose is metabolized to CO2 and water. Biliary/fecal: negligible.
Renal (primarily as unchanged drug and metabolites). Biliary/fecal excretion is negligible (<5%).
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution